Businesswire·2025-12-06 19:00Core Insights - Kite, a Gilead Company, and its partner Arcellx announced new positive data from the pivotal iMMagine-1 Phase 2 study of anitocabtagene autoleucel (anito-cel) [1] - The investigational agent continues to demonstrate clinically meaningful deep and durable efficacy in relapsed or refractory multiple myeloma (RRMM) patients who have received at least three prior lines of therapy [1] - Safety profiles observed to date are predictable and manageable [1] Summary by Categories Company Developments - Kite and Arcellx are advancing their research with anitocabtagene autoleucel, showing promising results in clinical trials [1] - The collaboration highlights the ongoing commitment to developing innovative therapies for challenging conditions like RRMM [1] Industry Implications - The positive data from the iMMagine-1 study may influence the treatment landscape for RRMM, potentially offering new options for patients with limited therapies available [1] - The findings could attract further investment and interest in CAR T-cell therapies within the oncology sector [1]